ArticleCureus2025
Hidden Cancer as the Cause of an Ischemic Stroke: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-related stroke is increasingly being recognized as a significant clinical entity. Multiple vascular territory involvement and elevated coagulation markers often serve as key indicators of the underlying malignancy in stroke patients, making their recognition crucial for early cancer detection. Here, we report a case of a 74-year-old woman who presented with progressive left-sided weakness developing over one week. Brain MRI revealed extensive multifocal acute infarcts involving bilateral cerebral and cerebellar hemispheres. Initial stroke workup showed no conventional risk factors. However, laboratory investigations revealed markedly elevated D-dimer (39.39 μg/mL), decreased fibrinogen (84.3 mg/dL), and elevated fibrinogen degradation product (109.91 μg/mL) levels, consistent with disseminated intravascular coagulopathy. Tumor screening demonstrated significantly elevated tumor markers (CA19-9: 28,960 U/mL, CA125: 394.6 U/mL), and imaging identified a hypervascular ovarian mass. Surgical resection confirmed right ovarian clear cell carcinoma. Postoperative follow-up showed improvement in coagulation parameters, and the patient remained stroke-free for six months under antiplatelet therapy. This case emphasizes the importance of maintaining clinical suspicion for occult malignancy in patients presenting with cryptogenic stroke, particularly when accompanied by multiple vascular territory involvement and elevated coagulation markers. Early recognition of these warning signs can lead to timely cancer diagnosis and appropriate management strategies, potentially improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.